Catalyst Pharmaceuticals (CPRX) Accumulated Expenses (2010 - 2025)

Catalyst Pharmaceuticals' Accumulated Expenses history runs 16 years deep, the most recent figure standing at $136.0 million for Q4 2025.

• Quarterly Accumulated Expenses rose 34848.59% year-over-year to $136.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $136.0 million (up 34848.59% YoY) and the FY2025 annual result came in at $136.0 million, up 34848.59% from the prior year.
• Accumulated Expenses was $136.0 million for Q4 2025 at Catalyst Pharmaceuticals, up from $119.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $136.0 million in Q4 2025 and bottomed at $347000.0 in Q2 2025.
• A 5-year average of $41.7 million and a median of $33.2 million in 2021 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 34848.59% in 2025, while the deepest fall reached 99.59% in 2025.
• Catalyst Pharmaceuticals' Accumulated Expenses stood at $24.3 million in 2021, then jumped by 120.68% to $53.6 million in 2022, then grew by 14.28% to $61.3 million in 2023, then sank by 99.37% to $389000.0 in 2024, then soared by 34848.59% to $136.0 million in 2025.
• Business Quant data shows CPRX's Accumulated Expenses at $136.0 million in Q4 2025, $119.6 million in Q3 2025, and $347000.0 in Q2 2025.